Free Trial
NASDAQ:MYL

Mylan (MYL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$15.86
$15.86
50-Day Range
$14.37
$15.86
52-Week Range
$12.75
$23.11
Volume
4,016 shs
Average Volume
6.49 million shs
Market Capitalization
$8.59 billion
P/E Ratio
29.92
Dividend Yield
N/A
Price Target
N/A

Mylan MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.51
Upright™ Environmental Score
News Sentiment
0.00mentions of Mylan in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
0.90%
From $4.46 to $4.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.96 out of 5 stars

Medical Sector

801st out of 917 stocks

Pharmaceutical Preparations Industry

365th out of 413 stocks

MYL stock logo

About Mylan Stock (NASDAQ:MYL)

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

MYL Stock News Headlines

2 Covered Call Ideas on Pfizer Stock
See More Headlines
Receive MYL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mylan and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2020
Today
5/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MYL
CUSIP
62853010
Fax
N/A
Employees
35,000
Year Founded
N/A

Profitability

Net Income
$16.80 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.50 billion
Cash Flow
$8.76 per share
Book Value
$23.02 per share

Miscellaneous

Free Float
N/A
Market Cap
$8.59 billion
Optionable
Optionable
Beta
1.45
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Robert J. Coury (Age 59)
    Exec. Chairman
    Comp: $1.83M
  • Ms. Heather Bresch (Age 51)
    CEO & Exec. Director
    Comp: $5.64M
  • Mr. Rajiv Malik (Age 59)
    Pres & Exec. Director
    Comp: $4.47M
  • Mr. Anthony Mauro (Age 47)
    Chief Commercial Officer
    Comp: $2.55M
  • Mr. Paul B. Campbell
    Chief Accounting Officer, Sr. VP & Corp. Controller
  • Ms. Melissa Trombetta
    Head of Global Investor Relations
  • Mr. Dennis Zeleny (Age 65)
    Chief Human Relations Officer
  • Ms. Deborah Autor
    Sr. VP, Head of Strategic Global Quality & Regulatory Policy
  • Mr. Bill Szablewski
    Head of Capital Markets
  • Mr. Joseph F. Haggerty
    Corp. Sec.

MYL Stock Analysis - Frequently Asked Questions

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) issued its quarterly earnings data on Friday, November, 6th. The company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.16 by $0.15. The business earned $2.97 billion during the quarter, compared to analysts' expectations of $3 billion. Mylan had a trailing twelve-month return on equity of 20.43% and a net margin of 2.35%. The company's revenue was up .4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.17 earnings per share.

What other stocks do shareholders of Mylan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Intel (INTC), NVIDIA (NVDA), Cisco Systems (CSCO), Starbucks (SBUX) and General Electric (GE).

This page (NASDAQ:MYL) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners